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We have previously described a DNA-packaging assay using bovine papillomavirus type 1 (BPV-1) virus-like particles
(VLPs) and have identified a region of the BPV genome that assists in packaging. In this study, we identify a specific BPV
sequence involved in DNA packaging by BPV-1 VLPs. In the initial screening of BPV-1 genomic sequences essential for DNA
packaging, we observed that a plasmid with deletions between nucleotides (nt) 948 and 2113 failed to be packaged into BPV-1
VLPs. However, plasmids containing nt 948 to 2113 were efficiently packaged, suggesting that this 1.2-kb fragment contains
a packaging enhancement sequence (PES). Further mapping of the BPV-1 genome showed that this packaging sequence lies
between nt 1506 and 1625. Furthermore, this packaging sequence is also recognized by HPV6b VLPs, suggesting that a
common packaging mechanism may be used by the two papillomavirus types. Given the phylogenetic difference between
these two viral types, it is likely that other papillomavirus types may also use the same packaging mechanism. Identification
of the PES has allowed a minimal viral genome sequence to be used in the packaging assay, improving the usefulness of the
assay in studying the process of papillomavirus DNA encapsidation. © 1999 Academic Press
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BINTRODUCTION
Papillomavirus (PV) is a small DNA virus that causes a
ariety of diseases, including some human cancers. The
irus does not replicate readily in conventional cultured
ells, which makes the study of viral replication difficult.
e have developed a novel system for studying papillo-
avirus DNA encapsidation (Zhao et al., 1998), a major
ate event in the viral life cycle. This in vitro system has
llowed us to systematically examine the requirements
nd conditions for viral DNA encapsidation, studying it in
solation from the other events in the viral replicative
ycle, such as cell infection, gene expression, and DNA
eplication. Our data have indicated that a specific PV
NA sequence is required for plasmid packaging (Zhao
t al., 1998). However, this sequence has not yet been
etermined. A specific region of the viral genome re-
uired for DNA or RNA packaging has been reported for
number of viruses. For example in SV40, a 200-bp DNA
ragment contains a signal for DNA encapsidation (Op-
enheim et al., 1992). In herpesvirus, an AT-rich se-
uence is essential for cleavage and packaging of DNA
McVoy et al., 1998), and sequences in pol are required
or the transfer of human foamy virus-based vectors
Erlwein et al., 1998). In papillomaviruses, DNA encapsi-
ation by VLPs at low efficiency has been reported by
everal groups (Zhou et al., 1993; Roden et al., 1994,
995, 1996; Unckell et al., 1997; Zhao et al., 1998; Stauffer
1 To whom correspondence and reprint requests should be ad-
pressed. Fax: 161-7-3240 2048.
211t al., 1998). DNA encapsidation by PV VLPs in vitro has
lso been studied by Touze and Coursaget (1998) and
awana et al. (1998), with most of these studies confirm-
ng that L2 plays a key role in DNA encapsidation or
nfection (Zhou et al., 1993; Roden et al., 1994, 1995, 1996;
hao et al., 1998; Stauffer et al., 1998; Kawana et al.,
998). Recently, data reported by Day et al. (1998) sug-
est a role for a nonstructural viral protein, E2, in virion
ssembly, specifically the recruitment of the viral ge-
ome to sites of assembly, through a high-affinity inter-
ction between E2 and specific viral DNA sequences. To
ate, however, no study focusing on sequences required
or specific encapsidation of papillomavirus genomic
NA has been reported. We have, therefore, carried out
series of experiments to define a sequence of the BPV
enome involved in DNA packaging.
RESULTS
ragment 948–2113 of BPV-1 contains a DNA
ackaging signal
Using a plasmid containing SV40 ori, ColE1 ori, and
he early regions of the BPV-1 genome as a target for
ackaging, we have established a system for packaging
NA into BPV-1 L11L2 VLPs, generated with a recom-
inant vaccinia virus (Zhao et al., 1998). The SV40 ori and
olE1 sequences allow the plasmid to replicate effi-
iently in large T antigen-expressing Cos-1 cells and in
acteria, respectively. This indicated that packaging by
PV-1 VLPs is more efficient if there is PV DNA within the
ackaged plasmid and demonstrated the size con-
0042-6822/99 $30.00
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212 ZHAO ET AL.traints on the packaged plasmid. In this study, we have
xtended our investigations to define PV sequences in-
olved in DNA packaging into papillomavirus VLPs. Plas-
id pSV BPV A was used as a parent plasmid to con-
truct a series of plasmids to map the BPV-1 sequence
ecessary for DNA packaging (Fig. 1, II). Using available
estriction sites within the BPV genome of pSV BPV A,
hree fragments of 1.0 kb (nt 3460–4450), 2.4 kb (nt
114–4450), and 3.5 kb (nt 948–4450) were separately
eleted. Each of the deleted BPV-1 sequences was re-
laced by a similar size DNA sequence derived from the
-gal gene to make the plasmids about 8 kb in length
Fig. 1, II).
These three plasmids, together with pSV BPV A as a
ositive control, were tested for their replication effi-
iency in Cos-1 cells and packaging into VLPs. Southern
lot analysis showed that the four plasmids replicated at
imilar rates in Cos-1 cells (Fig. 2, inset). When the
ackaging efficiencies of these four plasmids by BPV-1
LPs were compared in three separate experiments, we
ound that plasmids with a deletion of the 1.0-kb fragment
rom nt 3460 to 4450 and of the 2.4-kb fragment from nt
114 to 4450 produced similar numbers of bacterial col-
nies, comparable to those produced with the positive
ontrol plasmid pSV BPV A (data not shown). However,
eletion of 3.5 kb from nt 948–4450 resulted in a 10-fold
eduction in heavy VLPs (VLPs containing mostly full-size
lasmids) and a 25-fold reduction in light VLPs (VLPs
ontaining mostly truncated plasmids) (Fig. 2). These
esults suggested that the 1.2-kb fragment of the BPV-1
enome (from nt 945 to 2113) contained the sequence for
NA packaging into VLPs.
We also measured both the total amount of VLPs and
he amounts of VLPs that contained plasmids in the
eavy (Fig. 1, fraction 4) and light (Fig. 1, fraction 8)
ractions. The L1 protein of nonfractionated VLP prepa-
ations and that of the heavy and light VLP preparations
ere quantified by immunoblotting and densitometric
nalysis, with defined quantities of purified L1 protein
erving as the standard. A total of (3.18 6 1.21) 3 107
LPs were purified from 1 3 106 Cos-1 cells. The
mounts of VLPs that contained plasmids were calcu-
ated from the transformation assay using DNA prepared
rom VLP fractions. It is assumed that one packaged VLP
ontains one plasmid copy that can be either full-size or
runcated and which can form one colony after the plas-
id is purified and used to transform Escherichia coli.
he efficiency of transformation was determined using a
tandard plasmid. About 3.9% [(1.24 6 0.24) 3 106] of
ooled VLPs (heavy and light) contained plasmid DNA,
ith 1.4% [(4.43 6 0.55) 3 105] of heavy particles con-
aining plasmid when pSV BPV A was used for packag-
ng. But only 0.3% [(1.1 6 0.04) 3 105] of pooled VLPs and
.1% [(4.06 6 1.52) 3 104] of heavy VLPs contained
lasmid when pSV BPV D was used for packaging. hackaging enhancing sequence is located in a 400-bp
ragment (nt 1336–1725) of the BPV-1 genome
Based on the results from the initial sequence map-
ing experiments, we further investigated whether a
horter sequence within the 1.2-kb fragment of the BPV-1
enome contains a signal for DNA packaging into VLPs.
o this end, we used five pairs of primers (Table 1) to
roduce two 800-bp and three 400-bp BPV fragments by
CR, covering the whole 1.2-kb fragment identified
bove. These fragments were inserted into pSV BPV D at
he EcoRI site to produce a new series of plasmids (Fig.
, III). These newly constructed plasmids, together with
SV BPV A as a positive control and pSV BPV D as a
egative control, were further tested for their replication
fficiency in Cos cells and their packaging into VLPs.
gain, Southern blot analysis indicated that all five plas-
ids replicated equally well in Cos cells (Fig. 3, inset). At
his time, only the VLP suspension from Fraction 4 was
sed for DNA preparation and analysis of packaging
fficiencies. When the BPV-1 VLP packaging efficiencies
f the seven plasmids were compared in six separate
xperiments, we found that two plasmids containing the
00-bp sequence from nt 948 to 1725, or from nt 1336 to
113, produced similar numbers of plasmid-containing
LPs (data not shown), comparable to those produced by
he positive control plasmid pSV BPV A. The negative
ontrol plasmid produced only a tenth as many plasmid-
ontaining VLPs, indicating that both 800-bp regions of
he BPV-1 genome contained the DNA packaging en-
ancing sequence (data not shown).
However, the three plasmids containing a 400-bp se-
uence from nt 1725 to 2113, nt 1336 to 1725, or nt 948 to
335 showed different packaging efficiencies (Fig. 3),
lthough they replicated equally well in Cos cells (Fig. 3,
nset). Plasmid with the addition of the 400-bp sequence
rom nt 1725 to 2113 could not be packaged into VLPs,
ndicating that this region does not contain a DNA pack-
ging enhancing sequence. Although the plasmid with
he 400-bp sequence from nt 948 to 1335 showed im-
roved packaging efficiency (three times higher than that
f the negative control), the packaging efficiency was
elow that achieved by the positive control group, indi-
ating that the actual DNA packaging enhancing se-
uence may lie outside this fragment. Further testing of
he plasmid containing a 400-bp sequence from nt 1336
o 1725 revealed that it contained a packaging sequence
s it produced plasmid-containing VLPs at a similar
fficiency as the positive control plasmid (Fig. 3). These
esults suggested that the BPV-1 fragment from nt 1336
o 1725 enhances DNA packaging into BPV-1 VLPs.
he 120-bp (nt 1506–1625) fragment of BPV-1
nhances DNA packaging
To determine whether the BPV sequence that en-
ances DNA packaging is much shorter than the 400-bp
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213BOVINE PAPILLOMAVIRUS SEQUENCE ENHANCES DNA PACKAGINGFIG. 1. Plasmids used in the packaging assay. (I) BPV sequence. The enzyme sites are the clone sites used to construct the different plasmids.
he asterisk with an arrow indicates the position of a DNA sequence that assists in packaging. (II) Four plasmids used for initial mapping of BPV
equences essential for DNA packaging into VLPs. pSV BPV A, without L1/L2, was used as a parent plasmid to construct the three other plasmids.
SV BPV B resulted from pSV BPV A with a deletion of nt 3460 to 4450, replaced with 1 kb of the b-gal gene. pSV BPV C resulted from pSV BPV A
ith a deletion of nt 2114 to 4450, replaced with 2.4 kb of the b-gal gene. pSV BPV D resulted from pSV BPV A with a deletion of nt 948 to 4450, replaced
ith 3.4 kb of the b-gal gene. (III) Five plasmids, pSV BPV D1, pSV BPV D2, pSV BPV D3, pSV BPV D4, and pSV BPV D5, used for further mapping
f BPV sequence essential for DNA packaging into VLPs. pSV BPV D was used to construct the five plasmids with an insertion of about 800 or 400
p produced by PCR of the BPV genome within a 1.2-kb sequence from nt 948 to 2113. Each fragment was digested with EcoRI and cloned into pSV
PV D. 2.6 kb of the b-gal gene was cloned into pSV BPV D1 and pSV BPV D2 with the addition of an approximately 800-bp BPV fragment at the HindIII
ite. 3.0 kb of the b-gal gene was cloned into pSV BPV D3, pSV BPV D4, and pSV BPV D5 with the addition of an approximately 400-bp BPV fragment
t the HindIII site. (IV) Five plasmids, pSV BPV D6, pSV BPV D7, pSV BPV D8, pSV BPV D9, and pSV BPV D10, used for fine-mapping of the BPV
equence essential for DNA packaging into VLPs. pSV BPV D was again used to construct these five plasmids with insertion of a 120-bp fragment
roduced by PCR of BPV genome within a 500-bp sequence from nt 1206 to 1725. Each fragment was digested with EcoRI and cloned into pSV BPV
. 3.2 kb of the b-gal gene was separately cloned into these plasmids.
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214 ZHAO ET AL.ragment between nt 1336 and 1725, we conducted a
ine-mapping study. We used 10 primers (Table 1) to
roduce five fragments by PCR that covered the BPV
equence nt 1206 to 1725. Each fragment contained 120
p, overlapping its neighbors by 20 bp. These five frag-
ents were digested with EcoRI and separately cloned
nto plasmid pSV BPV D to produce five new plasmids
Fig. 1, IV). To ensure that these five plasmids have a size
imilar to that of the positive control plasmid pSV BPV A,
3.2-kb fragment of the b-gal gene was cloned into pSV
PV D at the HindIII site (Fig. 1, IV). The five plasmids
ere further tested in the packaging assay, along with
FIG. 2. Packaging of pSV BPV A and pSV BPV D by VLPs, measured
s the number of E. coli colonies produced by DNA extracted from VLP
ractions in a CsCl gradient, as described under Materials and Meth-
ds. Cos-1 cells were separately transfected with pSV BPV A and pSV
PV D and infected with rVV BPV-1 L1/L2. Data points are the average
f three separate experiments. (Inset) DNA replication of four plasmids
ransfected into Cos-1 cells was detected by Southern blot analysis: (1)
SV BPV A, (2) pSV BPV B, (3) pSV BPV C, and (4) pSV BPV D.
T
Oligonucleotide Primers Used for
No. Fragment Size (bp)
1 948–1725 777 59-CG
39-CG
2 1336–2113 777 59-CG
39-CG
3 948–1335 387 59-CG
39-CG
4 1336–1725 389 59-CG
39-CG
5 1726–2113 387 59-CG
39-CG
6 1206–1325 120 59-CC
39-CC
7 1306–1425 120 59-CC
39-CC
8 1406–1525 120 59-CC
39-CC
9 1506–1625 120 59-CC
39-CC
10 1606–1725 120 59-CC
39-CCSV BPV A and pSV BPV D4 as two positive controls and
SV BPV D as a negative control. Southern blot analysis
howed no difference in replication efficiency among
hese plasmids in Cos cells (Fig. 4, inset). Again, the VLP
uspension from Fraction 4 was used for DNA prepara-
ion and the packaging assay. Packaging assays clearly
ndicated that four plasmids containing a BPV-1 fragment
rom nt 1206 to 1325, 1306 to 1425, 1406 to 1525, or 1606
o 1725 were not packaged into VLPs (Fig. 4, I), although
estern blotting indicated that BPV L1 capsid protein
as expressed equally in Cos-1 cells (Fig. 4, II). How-
cation of BPV Fragments by PCR
Oligonucleotide primers
TCG GGG CAG GTG TAG AAC TGT CTG
TCG TAA AGC ACC ATG TTT AAG TGT AGC
TCA GCT GGG GCT CTT TAA ATC
TCC CTT TTA GCC AGA GCT TTA AAG
TCG GGG CAG GTG TAG AAC TGT CTG
TCT AAA AAC TGT AGC ATT TTT AGA
TCA GCT GGG GCT CTT TAA ATC
TCG TAA AGC ACC ATG TTT AAG TGT AGC
TCC TGA GTG GAT ACG GGC GCA AAC
TCC CTT TTA GCC AGA GCT TTA AAG
A TTC AAG CTT GAA GCT AAC CGT GTT CTT ACG CCC
A TTC AGC ATT TTT AGA TTT AAC AAG CTG
A TTC AAG CTT TTG TTA AAT CTA AAA ATG CTA CAG
A TTC CCC ATT GCT GAT TAG TGG TCT
A TTC AAG CTT GAC CAC TAA TCA GCA ATG GGT GCT GGC
A TTC TCA TGA GAT CTT TTT TGC ATC TGC ATC TGC
A TTC AAG CTT ATG CAA AAA AGA TCT CAT GAA GGA GGA
A TTC CTC TTC TCT TAC ATT TAG CGT GTT TGC
A TTC AAG CTT CGC TAA ATG TAA GAG AAG AGT GTT
A TTC GTA AAG CAC CAT GTT TAA GTG TAG CGG
FIG. 3. Packaging of five plasmids by VLPs, measured as the number
f E. coli colonies produced by DNA extracted from VLP suspensions,
s described under Materials and Methods. Cos-1 cells were sepa-
ately transfected with five plasmids and infected with rVV BPV-1 L1/L2.
ata are the average of six separate experiments. (A) pSV BPV A was
sed as a positive control; (B) pSV BPV D was used as a negative
ontrol; (C) pSV BPV D5; (D) pSV BPV D4; (E) pSV BPV D3. (Inset) DNA
eplication of five plasmids transfected in Cos-1 cells was detected by
outhern blot analysis: (1) pSV BPV A, (2) pSV BPV D, (3) pSV BPV D3,
4) pSV BPV D4, and (5) pSV BPV D5.ABLE 1
Amplifi
G AAT
G AAT
G AAT
G AAT
G AAT
G AAT
G AAT
G AAT
G AAT
G AAT
G GA
G GA
G GA
G GA
G GA
G GA
G GA
G GA
G GA
G GA
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215BOVINE PAPILLOMAVIRUS SEQUENCE ENHANCES DNA PACKAGINGver, the plasmid containing nt 1506–1625 of the BPV-1
enome was packaged into VLPs, as were the two pos-
tive control plasmids (Fig. 4, I). These results suggested
hat a 120-bp (nt 1506–1625) fragment of BPV is important
or DNA packaging.
PV sequence containing the DNA packaging
equence is recognized by HPV 6b L1
nd L2 capsid proteins
To examine whether the BPV-1 packaging signal can
e recognized by other PV VLPs, we tested whether pSV
PV D4 could be packaged by HPV6b VLPs. Plasmid
cDNA6bE1 was constructed for the packaging assay
Fig. 5, I): it contains nt 715–2778 from HPV 6b, which
robably includes a DNA packaging sequence. Plasmids
SV BPV A and pSV BPV D were again used as positive
nd negative controls, respectively. An immunoblotting
ssay indicated that HPV6b L1 protein was expressed in
os-1 cells (Fig. 5, III). Packaging assays showed that
SV BPV D was not packaged into HPV6b VLPs (Fig. 5,
I), whereas pcDNA6bE1 was efficiently packaged, indi-
ating that there is a DNA packaging sequence in 6bE1
orresponding to the packaging enhancing sequence
resent in pSV BPV A and pSV BPV D4, which were also
ackaged by HPV6b VLPs (Fig. 5, II).
DISCUSSION
In the present study, pSV BPV A, containing the entire
PV genome except for the L1 and L2 genes, was used
FIG. 4. Packaging assay of (I) eight plasmids by VLPs, measured as
he number of E. coli colonies produced by DNA extracted from VLP
uspensions, and Western blotting assay; (II) VLP suspensions, as
escribed under Materials and Methods. Cos-1 cells were separately
ransfected with eight plasmids and infected with rVV BPV-1 L1/L2.
ata for the packaging assay are the average of six experiments. (A)
SV BPV A and (C) pSV BPV D4 were used as two positive controls; (B)
SV BPV D was used as a negative control; (D) pSV BPV D6; (E) pSV
PV D7; (F) pSV BPV D8; (G) pSV BPV D9; and (H) pSV BPV D10. (Inset)
NA replication of six plasmids transfected into Cos-1 cells was
etected by Southern blot analysis: (1) pSV BPV A, (2) pSV BPV D6, (3)
SV BPV D7, (4) pSV BPV D8, (5) pSV BPV D9, and (6) pSV BPV D10.s a positive control plasmid to examine DNA packaging 6equences. We observed that deletions of sequences
overing the E5, E4, E3, E2, and E8 gene regions did not
ffect DNA packaging efficiency by BPV VLPs, indicating
hat these regions are not involved in DNA packaging.
he plasmid pSV BPV D, with a deletion of the E1 gene,
ailed to be effectively encapsidated, even though it con-
ained the E6 and E7 gene regions and the long control
egion (LCR) sequences, suggesting that the E1 gene
egion is involved in BPV DNA packaging. This observa-
ion is also supported by the experiment using
cDNA6bE1.
Studies carried out by Touze and Coursaget (1998) and
awana et al. (1998) have suggested that in vitro DNA
ncapsidation by HPV VLPs is independent of the HPV
NA sequence. However, they did not set out to com-
FIG. 5. (I) Plasmid pcDNA3 6b E1. (II) Packaging of four plasmids by
PV 6b VLPs, measured as the number of E. coli colonies produced by
NA extracted from VLP suspensions. (III) Western blotting assay of
LP suspensions, as described under Materials and Methods. Cos-1
ells were separately transfected with four plasmids and infected with
VV HPV 6b L1/L2. Data for the packaging assay are the average of four
xperiments. (A) pSV BPV A and (C) pSV BPV D4 were used as positive
ontrols; (B) pSV BPV D was used as a negative control; (D) pcDNA3 6b
1. (Inset) DNA replication of two plasmids transfected into Cos-1 cells
as detected by Southern blot analysis (1) pSV BPV A and (2) pcDNA3b E1.
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216 ZHAO ET AL.are plasmids with and without PV sequences. Also, the
lasmids used in these studies were smaller than the
.9-kb PV genome. Recently Stauffer et al. (1998) also
oncluded that DNA encapsidation by HPV 18 VLPs is
ndependent of the HPV DNA sequence after comparing
hree plasmids, with one containing only the long control
egion of the viral genome, but again without using plas-
ids that contained the rest of the genome. In our pre-
ious study, we determined whether plasmids containing
arious PV sequence were packaged into VLPs (Zhao et
l., 1998). We have found that 8.2 times as many VLPs
1.34 g/ml) were produced when a plasmid containing 5.4
b of BPV sequence was used than when plasmid
cDNA/purb, which lacked the PV sequences, was used.
n the present study, we observed that plasmid pSV BPV
, containing only the long control region of BPV, re-
ulted in a 10-fold reduction in packaging efficiency,
imilar to that found with pcDNA/purb. Results obtained
y Stauffer et al. (1998) and by us in the present study
ndicate that the PV LCR does not contain a packaging
ignal, leading Stauffer et al. (1998) to conclude that DNA
ncapsidation by HPV 18 VLPs is independent of HPV
NA sequences. Furthermore, plasmids pSV BPV D4
nd pSV BPV D9, which did not contain any intact ORFs,
ere efficiently packaged into BPV VLPs in the present
tudy, indicating that no viral protein is acting in trans
uring the packaging. Based on the results obtained in
he present study, together with our previous results
Zhao et al., 1998), we can conclude that DNA encapsi-
ation by BPV VLPs is enhanced by a specific DNA
equence in the papillomavirus genome and that a low
ercentage of VLPs can trap plasmid that does not con-
ain PV sequences. We have called this 120-bp sequence
packaging enhancement sequence (PES). Since the
ocus of our work is the study of DNA packaging by BPV,
he potential infectivity of VLPs that packaged the various
lasmids was not determined.
It is not clear whether any element within the PES is
onserved among other papillomavirus types. Previous
tudies have shown that various types of adenoviruses
se different packaging sequences (Robinson and Tib-
etts, 1984; Hearing et al., 1987). In the present study,
owever, the sequence important for BPV DNA packag-
ng was also recognized by HPV 6b VLPs. Considering
he phylogenetic difference between these two papillo-
avirus types, it is likely that other papillomavirus types
ay use the same packaging mechanism. In addition,
esults obtained in the present study have shown that the
CR of the BPV genome alone did not increase packag-
ng efficiency. However, it may be argued that there is a
ossibility that the LCR is necessary in combination with
he 120-bp sequence to support efficient packaging be-
ause the LCR is present in the plasmid construct, and it
as been observed in bacteriophage f6 that packaging
egment S must be in combination with segment L to
upport DNA packaging (Onodera et al., 1998). Based on fhe results obtained from the experiments using pcDNA
b E1, this possibility may be ruled out because no LCR
s present in this plasmid, which was efficiently pack-
ged into HPV 6b VLPs.
Data on cis sequences of viral genomes required for
NA or RNA packaging into VLPs have been found in
everal viruses (Hearing et al., 1987; Grable and Hearing,
992; Oppenheim et al., 1992; Zimmermann and Ham-
erschmidt, 1995; Kaye et al., 1995; Schmid and Hearing,
998; Heinkelein et al., 1998). Adenovirus (Ad) packaging
s dependent on the presence of a cis-acting sequence
nt 194–380) in the viral genome (Hearing et al., 1987;
rable and Hearing, 1992; Schmid and Hearing, 1998). In
V40, a cis-acting DNA signal for encapsidation is
resent within a 200-bp DNA fragment (Oppenheim et al.,
992). Zimmermann and Hammerschmidt (1995) reported
hat a cis-acting element is essential for cleavage of the
NA concatamers and encapsidation of the virion DNA
n Epstein–Barr virus. Two cis-acting elements are rec-
gnition signals for encapsidation in HIV (McBride and
anganiban, 1996; McBride et al., 1997) and in human
ytomegalovirus (Bogner et al., 1998). So far, there is no
vidence whether any cis-acting sequence of BPV is
nvolved in DNA packaging. An early study by Lusky and
otchan (1984) identified two cis-acting sequences
ermed PMS (plasmid maintenance sequences) in BPV,
hich function to maintain the genome as an episome in
ransformed and tumor cells. PMS-2 was mapped to a
40-bp segment between nt 1514 and 1654 within the E1
pening reading frame (Lusky and Botchan, 1984). In the
resent study, pSV BPV D9 contained the BPV PMS-2
nalyzed by Lusky and Botchan and was efficiently pack-
ged. However, a later publication from this group indi-
ated the difficulty in repeating the experiment to define
he BPV PMS sequences, which they concluded were
robably artifacts (Yang et al., 1991). Also, Nallaseth and
ePamphilis (1994) reported that BPV contains cis-acting
equences that overlap the PES that we have identified
nd which suppress origins of DNA replication, but their
ffect on DNA packaging was not assayed. Further in-
estigation is required to more precisely define the func-
ions of this region.
The BPV PES is AT-rich (more than 60% A1T), similar to
any other viral packaging signals, and the 120-bp size is
imilar to those reported in feline leukemia virus (FeLV),
pstein–Barr virus, and adenovirus. In FeLV, for example, a
07-nucleotide sequence comprises a packaging signal,
nd deletion of this sequence resulted in an approximately
00-fold reduction of packaged virions (Burns et al., 1996). A
equence of 159-bp, including 11-bp elements, contains the
ignal essential for DNA packaging in Epstein–Barr virus
Zimmermann and Hammerschmidt, 1995), and the se-
uence nt 194–356 facilitates encapsidation in adenovirus
ype 5 (Hearing et al., 1987). However, much shorter se-
uences required for DNA packaging have been reportedor other viruses. For example, only 24 bp in the 39 region of
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217BOVINE PAPILLOMAVIRUS SEQUENCE ENHANCES DNA PACKAGINGene 16 is a preferred packaging sequence in phage T4
Lin and Black, 1998). Two 6-bp, AT-rich sequences required
or specific DNA packaging have been identified in human
ytomegalovirus (Bogner et al., 1998). The 120-bp size of the
ES of BPV represents the minimal size that can be defined
sing our approach. More precise mapping of specific
lements within the PES will require using a series of short
ligonucleotides rather than the enzyme-cleaved fragments
sed in this study. Moreover, this approach may be com-
licated by the existence of multiple elements within the
ES that enhance packaging. Further studies of the mech-
nisms of papillomavirus DNA encapsidation using this
ssay are now under way in our laboratory.
MATERIALS AND METHODS
ecombinant vaccinia viruses
BPV-1 L11L2 and HPV 6b L11L2 recombinant vac-
inia viruses (rVVs) were constructed as described pre-
iously (Zhou et al., 1992). All the viruses were grown in
V-1 cells and plaque-purified three times.
onstruction of recombinant plasmids for packaging
Plasmid pSV BPV-1 L1/L2 (referred to as pSV BPV A, Fig.
, II), which contains the entire BPV-1 genome except for the
1 and L2 open reading frames, has been shown to contain
equences essential for DNA packaging by BPV capsids
Zhao et al., 1998). This plasmid was used as a parent
lasmid to construct a series of plasmids with deletions of
PV-1 sequences of up to 3.5 kb for the initial sequence
apping experiments (Fig. 1, II). A plasmid pSV BPV D
ontaining a b-gal gene (Fig. 1, II), derived from pSV BPV A
ith a 3.5-kb deletion of BPV from nt 948 to 4450, was used
s a template to construct another two series of plasmids
or fine sequence mapping experiments. It was found that
SV BPV D does not contain a sequence enhancing DNA
ackaging in initial sequence mapping experiments. Eight
airs of oligonucleotide primers (Table 1) were used to
mplify 10 fragments of the BPV genome covering nt 948 to
113. These 10 fragments produced by PCR were digested
ith EcoRI and cloned into EcoRI-cut pSV BPV D to con-
truct 10 plasmids. Three fragments of the b-gal gene, with
izes of 2.6, 3.0, and 3.2 kb, were individually cloned into
hese 10 plasmids at the HindIII site, giving plasmids of a
ize (about 8 kb) similar to that of the positive control
lasmid pSV BPV A (Fig. 1, III and IV). All 10 plasmids were
qually efficient at transforming E. coli, with 1 ng of plasmid
NA producing about 1000 colonies.
NA transfection and VLP preparations
Cos-1 cells, grown in Dulbecco’s modified Eagle’s me-
ium (DMEM) supplemented with 10% fetal bovine serum
FBS), were brought up to 70% confluence in 150-cm2 flasks.
ells were washed in OPTI-MEM medium (Gibco) andransfected with 10 mg of plasmid DNA using Lipofectamine mGibco) according to the supplier’s instructions. After trans-
ection, cells were grown for 36 h in DMEM supplemented
ith 10% FBS. The transfected cells were then infected with
VVs and grown at 37°C for 24 h and finally at 22°C for a
urther 24 h before use. For comparison of DNA transfection
nd replication of different plasmids, cells were collected,
elleted by centrifugation, and resuspended in lysis buffer
10 mM Tris–HCl, pH 7.5, 10 mM EDTA, 0.2% Triton X-100).
lasmid DNA was prepared by the Hirt (1967) method and
hen digested with DpnI and a single-cut enzyme, electro-
horesed on a 1% agarose gel, blotted onto a membrane,
nd probed with 32P-labeled DNA.
For preparation of VLPs, cells were pelleted by centrifu-
ation and washed with phosphate-buffered 0.15 M sodium
hloride (PBS), pH 7.4, containing 2 mM phenylmethylsul-
honyl fluoride (PMSF). Cell pellets were resuspended in 5
l of PBS containing PMSF and homogenized in a dounce
omogenizer with tight-fitting pestle for 10 min on ice. The
uclei released were collected by centrifugation at 3000
pm at 4°C for 15 min and resuspended in 10 ml of PBS with
MSF. This nuclear suspension was sonicated for 40 s on
ce, and the lysates were laid over 20% sucrose/PBS and
elleted by centrifugation at 26,000 rpm for 2 h using a
eckman SW28 rotor. The VLP pellets were resuspended in
1.5 ml of PBS containing 5.5 g CsCl and centrifuged in a
eckman SW41 rotor at 40,000 rpm at 21°C for 20 h. Frac-
ions were collected from the resulting gradient and were
sed for the analysis of encapsidated plasmid DNA.
xtraction and transformation of encapsidated
lasmid DNA
To prepare the encapsidated DNA from VLP fractions,
00 ml of VLP suspension from each CsCl gradient frac-
ion was dialyzed as described by Zhao et al. (1998). The
ialyzed VLP suspensions were then added to 5 units of
Nase and 5 units of RNase (Pharmacia) in 0.4 M Tris–
Cl buffer containing 60 mM MgCl, to bring the mixture
o 20 mM Tris–HCl and 3 mM MgCl at pH 7.0, and
igested at 37°C for 30 min. Three hundred microliters of
% sodium dodecyl sulfate (SDS) and 500 ml of phenol
ere added to each VLP suspension with gentle inver-
ion. The VLP–SDS–phenol mixtures were held in a wa-
er bath at 65°C for 30 min. The aqueous phase contain-
ng DNA was extracted with phenol–chloroform and
hloroform. DNA was precipitated with 50 ml of 3 M
odium acetate and 2 vol of 100% ethanol at 270°C for
h, pelleted by centrifugation at 14,000 rpm for 10 min,
nd resuspended in 20 ml of TE buffer. Two microliters of
NA was used to transform 40 ml of E. coli DH-5 a cells
ith a Gene Pulser (Bio-Rad). The transformed E. coli
ells were spread on ampicillin-containing LB plates and
ncubated at 37°C for 16 h. Ampicillin-resistant colonies
ere counted to measure the efficiency with which plas-
id DNA was packaged into VLPs.
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218 ZHAO ET AL.mmunoblotting of L1 capsid protein in VLP
uspensions
Three hundred microliters of nonfractionated VLP sus-
ension was precipitated with 1.2 ml acetone at 270°C for
h, and the protein pellets were collected by centrifugation
t 14,000 rpm for 15 min. These pellets were resuspended
n 50 ml of 13 Laemmli buffer (Laemmli, 1970) and boiled
or 5 min, and 10 ml of protein suspension was separated
n a 10% (w/v) SDS–PAGE gel and electrotransferred onto
itrocellulose membranes (Bio-Rad). Blots were washed
ith PBS for 10 min and then blocked in PBS containing 5%
onfat milk for 1 h. A polyclonal anti-BPV1 L1 antibody
Dako) was used to probe the capsid proteins. The blots
ere then incubated with HRP-conjugated, anti-rabbit anti-
ody (Silenus, Australia) at room temperature for 4 h and
eveloped by enhanced chemiluminescence (ECL, Amer-
ham, Australia).
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